Literature DB >> 10439825

Recommendations for the management of irritable bowel syndrome in family practice. IBS Consensus Conference Participants.

W G Paterson1, W G Thompson, S J Vanner, T R Faloon, W W Rosser, R W Birtwhistle, J L Morse, T A Touzel.   

Abstract

To help family physicians manage patients with irritable bowel syndrome (IBS), a consensus conference was convened in June 1997 at which 5 internationally recognized experts in IBS presented position papers on selected topics previously circulated to the conference participants. Five working groups comprising family physicians, gastroenterologists and allied health care professionals from across Canada were then charged with developing recommendations for the diagnosis, patient education, psychosocial management, dietary advice and pharmacotherapy, respectively. An evidence-based approach was used where possible; otherwise, recommendations were made by consensus. The participants concluded that family physicians can make a positive diagnosis of IBS using symptom criteria. The pathophysiology is poorly understood, but motility and sensory disturbances appear to play a role. Neither psychological nor specific dietary factors cause IBS, but both can trigger symptoms. Drug therapy is not recommended for the routine treatment of IBS, but short-term trials of drug therapy may be targeted to predominant symptoms in selected patients. A step-wise, patient-centred approach to management is outlined.

Entities:  

Mesh:

Year:  1999        PMID: 10439825      PMCID: PMC1230466     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  55 in total

Review 1.  The irritable bowel syndrome: review and a graduated multicomponent treatment approach.

Authors:  D A Drossman; W G Thompson
Journal:  Ann Intern Med       Date:  1992-06-15       Impact factor: 25.391

2.  Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study.

Authors:  M R Lucey; M L Clark; J Lowndes; A M Dawson
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

3.  Irritable bowel syndrome: prevalence, prognosis and consequences.

Authors:  W G Thompson
Journal:  CMAJ       Date:  1986-01-15       Impact factor: 8.262

4.  "Inflammatory" bowel disease.

Authors:  J F Fielding
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-05

Review 5.  Pain relief by antidepressants: possible modes of action.

Authors:  Charlotte Feinmann
Journal:  Pain       Date:  1985-09       Impact factor: 6.961

6.  Irritable bowel syndrome in the general population.

Authors:  R Jones; S Lydeard
Journal:  BMJ       Date:  1992-01-11

7.  Learned illness behavior in patients with irritable bowel syndrome and peptic ulcer.

Authors:  W E Whitehead; C Winget; A S Fedoravicius; S Wooley; B Blackwell
Journal:  Dig Dis Sci       Date:  1982-03       Impact factor: 3.199

8.  Is rectal biopsy necessary in irritable bowel syndrome?

Authors:  D G MacIntosh; W G Thompson; D G Patel; R Barr; M Guindi
Journal:  Am J Gastroenterol       Date:  1992-10       Impact factor: 10.864

Review 9.  Loperamide. Survey of studies on mechanism of its antidiarrheal activity.

Authors:  F Awouters; A Megens; M Verlinden; J Schuurkes; C Niemegeers; P A Janssen
Journal:  Dig Dis Sci       Date:  1993-06       Impact factor: 3.199

10.  Evaluation of Manning's criteria in the diagnosis of irritable bowel syndrome.

Authors:  K P Rao; S Gupta; A K Jain; A K Agrawal; J P Gupta
Journal:  J Assoc Physicians India       Date:  1993-06
View more
  10 in total

1.  Irritable bowel syndrome: could it be celiac disease?

Authors:  John Hoey
Journal:  CMAJ       Date:  2002-02-19       Impact factor: 8.262

2.  Diagnosing irritable bowel syndrome: what's too much, what's enough?

Authors:  Susan Lucak
Journal:  MedGenMed       Date:  2004-03-12

3.  Irritable bowel syndrome: are complementary and alternative medicine treatments useful?

Authors:  Richard V Birtwhistle
Journal:  Can Fam Physician       Date:  2009-02       Impact factor: 3.275

4.  Canadian Digestive Health Foundation Public Impact Series 3: irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact.

Authors:  Richard N Fedorak; Stephen J Vanner; William G Paterson; Ron J Bridges
Journal:  Can J Gastroenterol       Date:  2012-05       Impact factor: 3.522

5.  A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders.

Authors:  Edith Lahner; Stefano Bellentani; Rudy De Bastiani; Cesare Tosetti; Michele Cicala; Gianluca Esposito; Paolo Arullani; Bruno Annibale
Journal:  United European Gastroenterol J       Date:  2013-10       Impact factor: 4.623

Review 6.  IBS--review and what's new.

Authors:  Amy Foxx-Orenstein
Journal:  MedGenMed       Date:  2006-07-26

7.  Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting.

Authors:  Ron L Akehurst; John E Brazier; Nigel Mathers; Caroline O'Keefe; Eva Kaltenthaler; Anne Morgan; Maria Platts; Stephen J Walters
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 8.  Complementary and alternative medicine for treatment of irritable bowel syndrome.

Authors:  Yi-Hao A Shen; Richard Nahas
Journal:  Can Fam Physician       Date:  2009-02       Impact factor: 3.275

9.  Resource utilization associated with irritable bowel syndrome in the United States 1987-1997.

Authors:  Ya-Chen Tina Shih; Victoria E Barghout; Robert S Sandler; Priti Jhingran; Medha Sasane; Suzanne Cook; David C Gibbons; Michael Halpern
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

10.  Tegaserod (Zelnorm) for irritable bowel syndrome: reports of serious diarrhea and intestinal ischemia.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2004-06-22       Impact factor: 8.262

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.